ESR1 and neoplasm: In contrast, preclinical studies have shown that in ERα-negative, HER 2-positive breast cancers, AR promotes tumor growth through the AR/FOXA1/β-catenin complex which binds to the HER 3 gene, thereby inducing cancer cell proliferation (Figure 1) [10].